ACCELERATED COMMUNICATION

Acridinediones: Selective and Potent Inhibitors of the Malaria Parasite Mitochondrial bc₁ Complex

Giancarlo A. Biagini, Nicholas Fisher, Neil Berry, Paul A. Stocks, Brigitte Meunier, Dominic P. Williams, Richard Bonar-Law, Patrick G. Bray, Andrew Owen, Paul M. O’Neill, and Stephen A. Ward

Liverpool School of Tropical Medicine, Liverpool, United Kingdom (G.A.B., N.F., P.A.S., P.G.B., S.A.W.), Departments of Chemistry (N.B., R.B.-L., P.M.O.) and Pharmacology and Therapeutics (D.P.W., A.O.), University of Liverpool, Liverpool, United Kingdom; and Centre de Génétique Moléculaire, Centre National de la Recherche Scientifique, Gif-sur-Yvette, France (B.M.)

Received January 10, 2008; accepted February 29, 2008

ABSTRACT

The development of drug resistance to affordable drugs has contributed to a global increase in the number of deaths from malaria. This unacceptable situation has stimulated research for new drugs active against multidrug-resistant Plasmodium falciparum parasites. In this regard, we show here that deshydroxy-1-imino derivatives of acridine (i.e., dihydroacridinediones) are selective antimalarial drugs acting as potent (nanomolar \(K_i\)) inhibitors of parasite mitochondrial \(bc_1\) complex. Inhibition of the \(bc_1\) complex led to a collapse of the mitochondrial membrane potential, resulting in cell death (IC\(_{50}\) \(\sim\)15 nM). The selectivity of one of the dihydroacridinediones against the parasite enzyme was some 5000-fold higher than for the human \(bc_1\) complex, significantly higher (\(\sim\)200 fold) than that observed with atovaquone, a licensed \(bc_1\)-specific antimalarial drug. Experiments performed with yeast manifesting mutations in the \(bc_1\) complex reveal that binding is directed to the quinol oxidation site (Qo) of the \(bc_1\) complex. This is supported by favorable binding energies for in silico docking of dihydroacridinediones to \(P. falciparum bc_1\) Qo. Dihydroacridinediones represent an entirely new class of \(bc_1\) inhibitors and the potential of these compounds as novel antimalarial drugs is discussed.

Death and morbidity caused by malaria are on the increase, largely as a result of parasite drug resistance (Snow et al., 2001). Consequently, there are more people dying of malaria now than there were 20 years ago. Recognition of this problem by the international community and the engagement of the pharmaceutical industry and other key stakeholders has catalyzed the concerted search for new antimalarial drugs with novel targets (Biagini et al., 2003, 2005; Edwards and Biagini, 2006).

Acridine-based drugs have a long history in malaria chemotherapy. Mepacrine was the first synthetic antimalarial blood schizontocide used clinically (Wernsdorfer and Payne, 1991); the related drug pyronaridine has been used for nearly 20 years as a monotherapy to treat malaria in China (Shao, 1990). Pyramax, a pyronaridine-argesunate combination treatment, is currently undergoing phase III clinical trials (http://www.mmv.org). In addition, acridine congeners, including the acridones (Basco et al., 1994; Winter et al., 2006) and dihydroacridinediones (Dürckheimer et al., 1980; Dorn et al., 2001), have also demonstrated potent antimalarial activity, in some cases with good in vitro therapeutic indices (Winter et al., 2006).

Many acridine-based compounds can bind to heme (e.g., Chou and Fitch, 1993; Dorn et al., 1998, 2001; Auparakkitanon et al., 2003, 2006), the by-product of parasite hemoglobin digestion. Clinically relevant acridines, such as quinacrine and pyronaridine, are believed to confer almost all of their antimalarial activity through this interaction by preventing the crystallization of heme (Dorn et al., 1998;
A role for parasite mitochondria is implicated by a degree of cross-resistance between some dihydroacridinediones and atovaquone (Suswam et al., 2001), although this relationship is not conclusive and has not been demonstrated with allelically exchanged parasite lines. Furthermore, studies performed on beef-heart mitochondria revealed that alkyl-acridones inhibit a number of mitochondrial functions, including complex I (Oettmeier et al., 1992), complex II (Oettmeier et al., 1994) \( \text{bc}_1 \) complex, the membrane-bound complex containing two distinct quinone binding sites, \( Q_o \) (quinol oxidation), and \( Q_i \) (quinone reduction), and the ATP/ADP translocase (Oettmeier et al., 1995). By virtue of their structural similarity to alkyl-acridones, the potent (picomolar) antimalarial activity of newly synthesized haloalkoxyacridones (Winter et al., 2006) has been attributed to inhibition of mitochondrial \( \text{bc}_1 \) complex, although it is possible that for some of these compounds antimalarial activity is a consequence of heme binding.

In this study, we have investigated the antimalarial mode of action of two dihydroacridinediones, floxacrine and WR249685 (the \( S \)-enantiomer of WR243246), developed by the Walter Reed Army Institute of Research (Fig. 1) (Raether and Fink, 1979, 1982; Schmidt, 1979; Kesten et al., 1992; Dorn et al., 2001). Both of these compounds show heme binding and \( \text{bc}_1 \) inhibitory properties; however, whereas floxacrine kills parasites via a heme-mediated process, WR249685 is shown here to be a highly selective inhibitor of the \( Q_o \) of the \( P. \) falciparum \( bc_1 \) complex. The molecular nature of the selectivity of these drugs and their potential as novel antimalarial drugs is discussed.

**Materials and Methods**

**Parasite, Culture, and Drug Sensitivity Assays.** *P. falciparum* (3D7 strain) cultures consisted of a 2% suspension of O+ erythrocytes in RPMI 1640 medium (glutamine, and NaHCO\(_3\)) supplemented with 10% pooled human AB+ serum, 25 mM HEPES, pH 7.4, and 20 \( \mu \)M gentamicin sulfate (Trager and Jensen, 1976). Cultures were grown under a gaseous headspace of 4% \( O_2 \), 3% \( CO_2 \) in \( N_2 \) at 37°C. Parasite growth was synchronized by treatment with sorbitol (Lambros and Vanderberg, 1979). The sensitivity of *P. falciparum*-infected erythrocytes to various drugs was determined using the \( ^{3}H \)hypoxanthine incorporation method (Desjardins et al., 1979) with an inoculum size of 0.5% parasitemia (ring stage) and 1% hematocrit. IC\(_{50}\) values were calculated by using the four-parameter logistic method (Graphit program; Erithacus Software, Horley, Surrey, UK). To determine whether the antimalarial activity of two drugs is additive, antagonistic, or synergistic, parasite growth was tested by titration of the two drugs at fixed ratios proportional to their IC\(_{50}\) values. The fractional inhibitory concentrations of the resulting IC\(_{50}\) values were plotted as isobolograms (Berenbaum, 1978).

**Inhibition of in Vitro Hemozoin Formation.** Assays were performed based on the methods by Bray et al. (1999) and Stead et al. (2001). In brief, an aliquot of ghost erythrocyte membrane (100 \( \mu \)l) and FPIX (100 \( \mu \)l of 3 mM in 0.1 M NaOH) were mixed with an aliquot of 1 M HCl (10 \( \mu \)l) and sodium acetate (500 mM, pH 5.2) was added to give a volume of 900 \( \mu \)l in each tube. A series of drug concentrations were prepared in water, and 100 \( \mu \)l of each was added to the appropriate samples. Samples were mixed and incubated for 48 h at 37°C, with occasional mixing. After incubation, samples were centrifuged (15,000g, 15 min, 21°C), and the hemozoin pellet was repeatedly washed with 2% (w/v) SDS in 0.1 M sodium bicarbonate, pH 9.0, until the supernatant was clear (usually 3 to 4 times). After the final wash, the supernatant was removed, and the pellet was resuspended in 1 ml of 0.1 M NaOH and incubated for a further 1 h at room temperature. The hemozoin content was determined by measuring the absorbance at 400 nm. The concentration of drug required to produce 50% inhibition of hemozoin production (IC\(_{50}\)) was determined graphically as described for the drug sensitivity assays.

**Determination of Heme-Drug Dissociation Constants.** Heme-drug equilibrium constants were determined based on a UV-visible spectroscopic method (Egan et al., 1997). To provide a strictly monomeric heme (ferriprotoporphyrin IX) species in solution, heme (6 \( \mu \)M) was prepared in a HEPES (20 mM, pH 7.2)-buffered solution of 40% (v/v) DMSO (Egan et al., 1997). UV-visible titrations of antimalarial drugs chloroquine, amodiaquine, floxacrine, and WR249685 were performed monitoring the Soret band of the porphyrin (390–460 nm). The resulting titration curves were analyzed using a nonlinear curve-fitting program (Pro-Fit) and thermodynamic parameters were derived from modeling, assuming a 1:1 complex of drug and heme (Marques et al., 1996; Egan et al., 1997).
Preparation of *P. falciparum* Cell-Free Extracts. Free parasites were prepared from aliquots of infected erythrocytes (approximately 8 x 10^9 cells/ml) by adding 5 volumes of 0.15% (w/v) saponin in phosphate-buffered saline (137 mM NaCl, 2.7 mM KCl, 1.76 mM K$_2$HPO$_4$, 8.0 mM Na$_2$HPO$_4$, and 5.5 mM D-glucose, pH 7.4) for 5 min, followed by three washes in HEPES (25 mM)-buffered RPMI containing a protease inhibitor cocktail (Complete Mini; Roche, Mannheim, Germany). A cell extract was prepared by repeated freeze-thawing in liquid N$_2$, followed by disruption with a sonicating probe.

**Human Liver Microsome Preparation.** Histological normal liver was obtained from white transplant donors. The certified cause of death was traumatic injury due to a automobile accident. The liver samples were transferred to the laboratory within 30 min of death. They were portioned, frozen in liquid nitrogen, and stored at −80°C. Approval was granted by the Liverpool local research Ethics Committee, and prior consent was obtained from the donors’ relatives.

Liver tissue was washed briefly in ice-cold isolation buffer (0.154 M KCl and 50 mM Tris-HCl, pH 7.4). The tissues were homogenized in 4× volume of isolation buffer and then centrifuged (10,000 g, 20 min, 4°C). The pellet was discarded and the supernatant was then centrifuged (105,000 g, 60 min, 4°C). The microsomal pellet was washed by resuspension in fresh buffer and centrifuged again (105,000 g, 60 min, 4°C). Microsomes were resuspended in 2× volume of 0.12 M Tris, pH 7.4, and stored frozen (−80°C) in 1 ml aliquots at 80°C.

**Preparation of Yeast Cytochrome b Mutants.** Generation of mutant strains and preparation of crude mitochondrial membranes was performed as described previously (Fisher et al., 2004b). Bovine Mitochondrial Membrane Preparation. Bovine mitochondrial membranes (Keilin-Hartree particles) were prepared as described by Kuboyama et al. (1972).

**Rat Liver Microsome Preparation.** Adult male Wistar rats were obtained from Charles River Laboratories (Margate, Kent, UK). Wistar rat liver microsomes were prepared from male rats (125–170 g) as described by Gill et al. (1995).

**Preparation of Decylubiquinol.** The artificial quinol electron donor was prepared based on the method of Fisher et al. (2004b). In brief, 2,3-dimethoxy-5-methyl-1,4-decylquinone (decylubiquinone), an analog of ubiquinone, was dissolved (10 mg) in 400 μl of nitrogen-saturated hexane. An equal volume of aqueous 1.15 M sodium dithionite was added, and the mixture shaken vigorously until colorless. The upper, organic phase was collected, and the decylubiquinol recovered by evaporating the hexane under N$_2$. The decylubiquinol was dissolved in 100 μl of 96% ethanol (acidified with 10 mM HCl) and stored in aliquots at −80°C.

Decylubiquinol concentration was determined spectrophotometrically from absolute spectra, using ε$_{286-290}$ = 4.14 M$^{-1}$ cm$^{-1}$.

**Measurement of bc$_1$ Activity.** Cytochrome c reductase activity measurements were assayed in 50 mM potassium phosphate, pH 7.5, 2 mM EDTA, 10 mM KCN, and 30 μM equine cytochrome c (Sigma Chemical, Poole, Dorset, UK) at room temperature (Fisher et al., 2004b). Cytochrome c reductase activity was initiated by the addition of decylubiquinol (50 μM). Reduction of cytochrome c was monitored in a Cary 4000 UV-visible spectrophotometer (Varian, Inc., Palo Alto, CA) at 550 versus 542 nm.

Initial rates (computer-fitted as zero-order kinetics) were measured as a function of decylubiquinol concentration. The cytochrome c content of membranes was determined from the dithionite-reduced minus ferricyanide-oxidized difference spectra, using ε$_{562-575}$ = 28.5 M$^{-1}$ cm$^{-1}$ (Vanneste, 1966). Turnover rates of cytochrome c reductase were determined using ω$_{550-542}$ = 18.1 M$^{-1}$ cm$^{-1}$ (Margoliash and Walasek, 1967).

**Inhibitors of bc$_1$ activity were added without prior incubation. DMSO in the assays did not exceed 0.3% (v/v).** IC$_{50}$ values were calculated using the four-parameter logistic method (Grafit). The equilibrium dissociation constant (K$_d$) of inhibitor binding to bc$_1$ was determined using the Cheng-Prusoff equation (Cheng and Prusoff, 1973).

**Real-Time Single-Cell Monitoring of Membrane Potential.** The rhodamine derivative tetramethylrhodamine ethyl ester (TMRE) was used to monitor the mitochondrial membrane potential (ΔΨ$_m$) of the plasma membrane and mitochondria of malaria-infected red blood cells (Biagini et al., 2006). TMRE is cationic and reversibly accumulates inside energized membranes according to the Nernst equation. For experimentation, suspensions (1%) of infected erythrocytes in HEPES-buffered RPMI 1640 medium (no serum) were loaded with TMRE (250 nM; Invitrogen, Carlsbad, CA) for 10 min at 37°C. For imaging, malaria parasite-infected erythrocytes were immobilized using polylysine-coated coverslips in a perfusion chamber (FCS2; Biopsticks, Butler, PA) and maintained at 37°C in growth medium (no serum). Inhibitors were added to the perfusate, and the mitochondrial membrane-potential-dependent fluorescence responses were monitored in real time. During all manipulations, the concentration of TMRE in the perfusate was kept at 250 nM. The fluorescence signals from malaria-infected erythrocytes were collected on a confocal laser scanning microscope (Pascal; Zeiss, Welwyn Garden City, UK) through a Plan-Apochromat 63 × 1.2 numerical aperture water objective. Excitation of TMRE was performed using the HeNe laser line at 543 nm. Emitted light was collected through a 560-nm long pass filter from a 543-nm dichroic mirror. Photobleaching (the irreversible damage of TMRE producing a less fluorescent species) was assessed by continuous exposure (5 min) of loaded cells to laser illumination. For each experiment, the laser illumination and microscope settings (e.g., laser power both voltage settings and attenuation [%], scan speed, pinhole diameter, number of scan sweeps, and degree of magnification) that gave no reduction in signal were used. Data capture and extraction were carried out with Zeiss Pascal software and Photoshop.

**Dihydroacridinedione Docking into *P. falciparum* Cytochrome b (Qo).** A predicted model of the *P. falciparum* cytochrome b of the bc$_1$ complex was constructed with SWISS-MODEL using bovine cytochrome b Protein Data Bank coordinate sets 1ntmC, 1sqxC, 110nc, 1ntkC, and 1be3c as the structural templates. In silico docking was performed using Autodock 3.05 (Morris et al., 1998) and associated suite of programs. Autodock uses an empirical scoring function to estimate the free energy of binding. This function contains five terms: A Lennard-Jones 12-6 dispersion/repulsion term; a directional 12-10 hydrogen bonding term; a screened Coulombic electrostatic potential; unfavorable entropy of binding due to restricted conformations; and a desolvation energy term. For the calculations, the protein atoms were kept fixed with the inhibitors allowed full flexibility. A combination of a Lamarckian genetic algorithm and pseudo-Solis and Wets local search was used to generate docking poses for each molecule. The docking was performed using a grid much larger than either the Q$_o$ or Q$_b$ binding sites. The parameters used in this blind docking procedure were those that have been shown to reproduce the binding mode of drugs within known structures of drug-crystal complexes with no prior knowledge of the binding site (Hetenyi and van der Spoel, 2002). The most favorable docking pose for each molecule was identified by the scoring function.

**Results**

**Dihydroacridinedione Binding to Heme.** Assays were performed to determine the affinity of dihydroacridinediones for heme as well as to determine their ability to inhibit heme crystallization relative to known heme-binding drugs. Chloroquine and chloroquine (CQ) were shown to inhibit heme crystallization with IC$_{50}$ values of 63 and 56 μM, respectively. WR249685 inhibited hemozoin formation by 50% at 130 μM; however, complete inhibition was not measurable because this was the highest concentration achievable in the assay (values are means of three independent determinations).

**Heme-drug equilibrium constants were determined for CQ, amodiaquine (AQ),* falciparum,* and WR249685 by mea-
suring the shift of the heme Soret band on titration of drugs. In buffered DMSO [40% (v/v)] solutions, the heme drug dissociation constants ($K_d$) were calculated to be; 1.38 
$\mu$M for CQ, 1.55 $\mu$M for AQ, 1.87 $\mu$M for floxacin, and 31.74 $\mu$M for WR249685 (values means of two independent determinations). The relative poor heme binding affinity of WR249685 was in contrast to its potent in vitro antimalarial activity (IC$_{50}$ 15 nM), which was comparable with that for CQ (IC$_{50}$ 7.4 nM), AQ (IC$_{50}$ 4.5 nM), and significantly better than that for floxacin (IC$_{50}$ 140 nM, Table 1).

**Dihydroacridinediones Inhibit P. falciparum bc$_1$ Activity.** The ability of floxacin and WR249685 to inhibit bc$_1$ complex activity was determined in a number of species and compared with that of well known bc$_1$ inhibitors (Fig. 1). For all species, bc$_1$ activity was determined by monitoring the reduction of cytochrome c with decylubiquinol (QH$_2$) as electron donor.

*P. falciparum* bc$_1$ activity exhibited Michaelis-Menten kinetics with an apparent concentration of substrate to lead to half-maximal velocity ($K_m$) for QH$_2$ of 6.2 ± 2 $\mu$M reaching a maximum at limiting velocity ($V_{max}$) of 576 ± 88 nmol of cytochrome c reduction s$^{-1}$ mg$^{-1}$ free parasite protein (Fig. 2A). Human bc$_1$ displayed similar saturation kinetics with a $K_m$ for QH$_2$ of 7.8 ± 2 $\mu$M and a $V_{max}$ turnover of 3 s$^{-1}$ (Fig. 2B). Note that turnover (seconds$^{-1}$) for *P. falciparum* cell-free extracts could not be determined as a result of interference of free heme and hemozoin with cytochrome b determinations. Both *P. falciparum* and human liver bc$_1$ activities could be stimulated ≥10-fold by addition of surfactant [0.025% (w/v) dodecyl maltoside]. However, to compare data with similar studies (Fry and Pudney, 1992), all inhibitory assays were performed in the absence of surfactant.

Inhibition profiles of bc$_1$ complexes from bovine heart, rat liver, human liver, and *P. falciparum* are described in Table 1. The bc$_1$ complexes from all species were shown to be similarly sensitive to the well-known bc$_1$ inhibitors stigmatellin, and myxothiazol. The antimalarial drug atovaquone displayed selective inhibition for *P. falciparum* bc$_1$ complex (IC$_{50}$ 3 ± 2 nM; $K_v$ 0.3 nM) over mammalian bc$_1$ complexes. It is noteworthy, however, that human and bovine bc$_1$ activity was observed to be more sensitive to atovaquone (IC$_{50}$ 72 and 83 nm, respectively) compared with rat liver bc$_1$ activity (IC$_{50}$ 406 nM). Likewise, albeit more modestly, the pyridone GW844520 displayed selective toxicity for the parasite enzyme (IC$_{50}$ 32 nM) over mammalian enzymes (IC$_{50}$ values ranging from 51 to 353 nM). The dihydroacridinedione WR249685 was shown to be selective exclusively for *P. falciparum* bc$_1$ complex (IC$_{50}$ 3 nM; $K_v$ 0.3 nM). It is noteworthy that the in vitro therapeutic index (TI) for this inhibitor against human bc$_1$ was >4600. This dramatic selectivity is significantly higher than that observed with atovaquone (TI = 24) or with the pyridone GW844520 (TI = 5). Floxacin was shown to have moderate inhibitory activity against cross-species bc$_1$ activities (IC$_{50}$ values ranging from 328 to 1458 nM) but without any selectivity over the *P. falciparum* enzyme.

**Inhibition of Yeast bc$_1$ Complex by Dihydroacridinediones Is Specific to the Quinol Oxidation Site (Q$_o$).** The inhibitory profile of the dihydroacridinediones was determined against wild type and genetically engineered *Saccharomyces cerevisiae* harboring cytochrome b mutations Y279S and G143A. The Y110S mutation corresponds to the atovaquone-resistant phenotype (Srivastava et al., 1999; Syafruddin et al., 1999; Korsinczky et al., 2000; Fisher and Meunier, 2005). The G143A mutation confers dramatic resistance to heme-proximal Q$_o$ inhibitors such as myxothiazol (Fisher et al., 2004a; Fisher and Meunier, 2005). As expected, atovaquone was shown to have potent bc$_1$ inhibitory activity against wild-type yeast (IC$_{50}$, 3 nM) and G143A mutants (IC$_{50}$ 27 nM), whereas the Y279S mutation conferred significant resistance (IC$_{50}$, 2689 nM, Table 2). Note that the Y279S mutation was also associated with a moderate increase in tolerance to the pyridone GW844520, floxacin, and WR249685 (Table 2). Taken together, these data indicate that all of these inhibitors target the Q$_o$ site of the bc$_1$ complex.

**Dihydroacridinediones Collapse Mitochondrial Membrane Potential.** The measurement of ΔΨ$_m$ was based on the accumulation of the cationic fluorescence probe TMRE according to the Nernst equation. Addition of TMRE to *P. falciparum*-infected erythrocytes resulted in a strong fluorescence signal originating from the parasite cytosol, denoting the existence of a high ΔΨ$_m$. This phenomenon has been observed previously (Biagini et al., 2006) and is the result of the high ΔΨ$_m$ (−100

---

**Table 1**

<table>
<thead>
<tr>
<th>Inhibitor</th>
<th>IC$_{50}$ bc$_1$ Inhibition</th>
<th>K$_v$</th>
<th>IC$_{50}$</th>
<th>K$_v$</th>
<th>IC$<em>{50}$ Growth Inhibition IC$</em>{50}$</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>nM</td>
<td>Human Liver</td>
<td>nM</td>
<td>nM</td>
<td>nM</td>
</tr>
<tr>
<td>Stigmatellin</td>
<td>2.4</td>
<td>15 ± 0.2</td>
<td>2</td>
<td>12 ± 1</td>
<td>1</td>
</tr>
<tr>
<td>Myxothiazol</td>
<td>8.4</td>
<td>15 ± 1</td>
<td>2</td>
<td>3.5 ± 0.5</td>
<td>0.4</td>
</tr>
<tr>
<td>Atovaquone</td>
<td>83 ± 23</td>
<td>72 ± 9</td>
<td>10</td>
<td>3 ± 2</td>
<td>0.3</td>
</tr>
<tr>
<td>Pyridone (GW844520)</td>
<td>51 ± 9</td>
<td>153 ± 16</td>
<td>21</td>
<td>32 ± 13</td>
<td>3.5</td>
</tr>
<tr>
<td>WR 249685</td>
<td>&gt;13,800</td>
<td>&gt;13,800</td>
<td>N</td>
<td>3 ± 2</td>
<td>0.3</td>
</tr>
<tr>
<td>Floxacin (racemic)</td>
<td>328 ± 65</td>
<td>1458 ± 280</td>
<td>198</td>
<td>803 ± 183</td>
<td>89</td>
</tr>
</tbody>
</table>

N, not determinable; N.D., not done.

a Assays contained 30 nM cyt b.

b Assays contained 7 nM cyt b.

c Assays contained 30 nM cyt b.
mV) of the plasma membrane (Allen and Kirk, 2004). Upon addition of the V-type H$^+$ ATPase inhibitors bafilomycin A$_1$ or concanamycin (200 nM), approximately 70 to 80% of the fluorescence signal was lost (data not shown), leaving a small but strong signal originating from the parasite mitochondrial (Biagini et al., 2006).

Because both the plasma membrane and the mitochondrial $\Delta\Psi_{\text{m}}$ contribute to the accumulation of TMRE, we could not accurately quantify the finite $\Delta\Psi_{\text{m}}$ values. Therefore, for all experiments, the fluorescence dynamic range was set up so that untreated TMRE-loaded cells were regarded as having complete fluorescence (100%), whereas the baseline (0%) was set by addition of the protonophore FCCP (10 $\mu$M). For mitochondrial-dependent fluorescence, bafilomycin A$_1$-treated cells were normalized to 100%; again, the baseline (0%) was set by FCCP (10 $\mu$M).

Addition of the dihydroacridinediones WR249685 (Fig. 3A) and floxacrine (data not shown) was observed to partially reduce (~20%) the total cellular $\Delta\Psi_{\text{m}}$-dependent TMRE fluorescence, possibly indicating an effect on the mitochondrial contribution. This view was confirmed by the reduction of $\Delta\Psi_{\text{m}}$-dependent fluorescence from bafilomycin A$_1$-treated parasites with WR249685 (Fig. 3B) and floxacrine (not shown).

**Discussion**

In this study, the mode of action of two potent antimalarial dihydroacridinediones has been investigated. Acridine derivatives have been considered to owe their antimalarial activity to their ability to bind heme. Therefore, we first investigated the relative heme binding properties of floxacrine and WR249685. Thermodynamic analysis of heme-binding revealed that both inhibitors could bind to heme with a rank order relative to other well known heme binding drugs of CQ > AQ > floxacrine > WR249685. The heme-drug equilibrium constants for CQ and AQ closely match those reported previously by other workers (Egan et al., 1997). CQ, floxacrine and to a lesser extent WR249685 were shown to be able to inhibit in vitro hemoglobin formation. These data are consistent with that of Dorn et al. (2001), which showed a comparable rank order of inhibition of in vitro hemoglobin formation [i.e., CQ > floxacrine > WR243246 (the 6R-enantiomer of WR249685)]. The relative poor heme binding affinity of floxacrine compared with CQ and AQ is reflected by the lower in vitro antimalarial activity (i.e., floxacrine IC$_{50}$ 140 nM, compared with CQ IC$_{50}$ 7.4 nM, and AQ IC$_{50}$ 4.5 nM). However, WR249685 demonstrated potent in vitro antimalarial activity (IC$_{50}$ 15 nM) and a >20-fold poorer affinity for heme compared with the other antimalarial drugs.

As concluded by Dorn et al. (2001), it seems that heme does...
not play a major role in the mode of action of all dihydroacridinediones. Given that related dihydroacridinediones have been shown to affect respiration of *P. falciparum* (Suswam et al., 2001), we next investigated whether the mode of action of WR249685 was related to the inhibition of respiratory components.

Mild cross-resistance (4- to 9-fold) of a dihydroacridinedione (WR243251) has been described in *P. falciparum* strains displaying 8700- to 23,000-fold resistance increase in atovaquone (Suswam et al., 2001). Although these parasite lines also displayed an increase in resistance to other antimalarials such as CQ, because the site of action of atovaquone is the *bc*₁ complex (Fry and Pudney, 1992), this respiratory component was chosen for investigation.

The *bc*₁ complex is a membrane-bound enzyme catalyzing the transfer of electrons from ubiquinol to cytochrome *c* coupled with the concomitant vectorial translocation of protons across the inner mitochondrial membrane (Crofts, 2004). The catalytic core of the enzyme is made up of cytochrome *b*₁, cytochrome *c*₁, and the Rieske iron-sulfur protein (ISP). The catalytic mechanism, known as the Q-cycle (Mitchell, 1975; Crofts, 2004), involves two distinct quinone binding sites within cytochrome *b*, the quinol oxidation site Qₒ and the quinone reduction site Qᵢ (Crofts, 2004). These two sites are situated on opposite sides of the membrane linked by a transmembrane electron pathway via hemes *b*₁ and *b*₂ (Crofts, 2004). A number of inhibitors selective for *bc*₁, Qₒ, and Qᵢ sites have been developed over recent years, most notably to control crop and human pathogens (Crofts et al., 1999; Esser et al., 2004; Fisher et al., 2004a).

In our study, stigmatellin, which binds in the *b*₁ distal domain of Qₒ (close to the docking site of ISP) (Crofts et al., 1999) and myxothiazol, which binds in the *b*₁-proximal position (Crofts et al., 1999), were both shown to be potent broad spectrum *bc*₁ inhibitors (Table 1). It is noteworthy, however, that inhibition of *bc*₁ activity by the dihydroacridinediones, pyridone, and naphthoquinone was highly species selective (Table 1).

Species selectivity was most notably demonstrated by WR249685, which displayed a *K₅₀* for *P. falciparum* of 0.3 nM and an in vitro TI against human *bc*₁ of >4600 (Table 1). Yeast carrying the Y279S mutation in cytochrome *b* (corresponding to the Y268S mutation in *P. falciparum* conferring atovaquone resistance (Srivastava et al., 1999; Syafruddin et al., 1999; Korsinczky et al., 2000; Fisher and Meunier, 2005)) were observed to be less sensitive to WR249685, suggesting that Qₒ is the binding site for this inhibitor (Table 2). So what is it about the *P. falciparum* *bc*₁ Qₒ site that lends itself to inhibition by WR249685?

X-ray crystallography has shown that the overall fold of the α-carbon backbone of cytochrome *b* is highly conserved in prokaryotic and eukaryotic organisms (Fig. 5A). However, despite the high degree of sequence and structural conservation, there are notable differences in key regions of the malaria parasite Qₒ site. Significantly, a homology model of the *P. falciparum* cytochrome *b* (constructed with SWISS-MODEL using bovine cytochrome *b* atomic coordinates as the structural template) suggests that the four-residue deletion in the cd3 helix results in a 13-Å displacement of this structural element compared with the mammalian enzyme (Fig. 5B). Likewise, the α-carbon atom of the N-terminal proline of the ef helix (containing the catalytically essential ‘PEWY’ motif) is predicted to be displaced by 2 Å compared with the mammalian enzyme. Other important differences include the replacement of lysine (269) by valine and alanine (277) by phenylalanine in the *P. falciparum* ef helix, and the exchange of phenylalanine (140) for tyrosine in the cd1 helix. Docking of WR249685 (and floxacin; data not shown) to the *P.
falciparum bc₁ Qₐ model was energetically favorable (binding energy, −8.1 kcal/mol; Fig. 6B); in addition, the model demonstrated selectivity in the docking of traditional Qₐ and Qₐ inhibitors (e.g., famoxadone and antimycin; data not shown).

Figure 6B shows Qₐ site residues predicted to be within 4 Å of the bound WR249685 (most energetically favorable conformation). The interactions are predominantly hydrophobic, although a backbone hydrogen bond from Ser241 to the aromatic secondary amine of WR249685 is likely to be important for the positioning of the compound at Qₐ. The glutamyl side chain of Glu261 shows considerable mobility and may also be involved in weak dipolar interactions with the chlorine atoms of WR249685. The most striking feature of the model for WR249685 binding to P. falciparum cytochrome b is the putative association between the inhibitor and the E-ef linker region (residues 236–241) of the cytochrome (Figs. 5A and 6B), a region of low sequence identity between P. falciparum and mammalian cytochrome b. The E-ef linker has not previously been recognized as a component of the Qₐ site in the elucidated bc₁ crystal structures, and thus may explain the very high degree of selectivity of WR249685 for the P. falciparum enzyme.

It is necessary, however, to be circumspect in the interpretation of the modeling data. It should be noted that “structural” water molecules at Qₐ were not included in the modeling process, and these may influence the binding energy and positioning of WR249685. In addition, the Rieske ISP headgroup was omitted during the modeling process, which has two important consequences. First, the loss of a potential hydrogen-bond donor to the Qₐ site via [2Fe-2S] cluster ligand His-161 (Esser et al., 2004); second, the steric volume occupied by the ISP is absent, which may allow for nonphysiological but otherwise energetically favorable in silico docking of bulky inhibitors at Qₐ.

The 5.6-fold increase in IC₅₀ for atovaquone in rat liver
microsome preparations compared with the human equivalent (Table 1) is, at first sight, surprising given the sequence homology between these species in the cd1 and regions of cytochrome b (Fig. 5A). It is possible that this difference is due to slight variation in the local fold and protein environment around \( Q_0 \), but a minor change in hydrogen-bonding capacity in the C-terminal region of transmembrane helix C may also weaken the interaction with atovaquone, raising the binding energy required for a stable association. It is noteworthy that bovine and human cytochrome b possess a potential \( Q_0 \)-site hydrogen bond donor in the forms of Thr121 and Thr122, respectively, that are absent in rat. In addition, there is conservative variation in the aliphatic composition of the F1 helix between these three species, which may result in an unfavorable ionic environment for atovaquone binding in rat cytochrome b.

In a similar fashion, the pyrione GW844520, shown to be specific for the \( bc_1 \), \( Q_0 \) site (Table 2), also displayed a 2-fold selectivity for human \( bc_1 \) over the rat enzyme (Table 1), with an in vitro TI against human \( bc_1 \) of only 5 (Table 1). The drug development of this particular pyrionone was terminated in late 2005 by the Medicines for Malaria Venture (MMV) because of toxicity issues (http://www.mmv.org). Currently a new pyrione (GSK932121A) is being developed with reduced toxicity. It will be interesting to establish whether this compound has an improved TI against human \( bc_1 \).

To our knowledge, this study is the first to report human liver \( bc_1 \) activity. At this stage, we have no idea of interspecies variation of \( bc_1 \) activities; nonetheless, our data indicate that rat liver enzyme is a poor model for human \( bc_1 \), and therapeutic indices generated from rat liver data should be treated with a degree of caution.

Addition of dihydroorucedinediones to malaria-infected erythrocytes was shown to cause the depolarization of \( \Delta \Psi_m \) (Fig. 3). We hypothesize that the depolarization of \( \Delta \Psi_m \) leads to a loss mitochondrial function and parasite death. Given that during the intraerythrocytic stage of the malaria life cycle, the parasite relies mainly on fermentation of glucose, the essential role(s) of the mitochondrion is not known, but it probably includes orotate production for pyrimidine biosynthesis (Gutteridge et al., 1979; Hammond et al., 1985) and \( Ca^{2+} \) homeostasis (Uyemura et al., 2000; Gazzara and Gar- 

ic, 2004). Furthermore, the close juxtaposition of the mitochon- drion with the plastid suggests an interdependence for essential metabolism (Goodman et al., 2007; Kobayashi et al., 2007).

It has recently been reported that addition of atovaquone does not cause a depolarization of parasite \( \Delta \Psi_m \) because \( \Delta \Psi_m \) is generated by the ATP synthase and adenine nucleotide translocator operating in reverse (Painter et al., 2007). We have questioned these conclusions (Fisher et al., 2008), however, and maintain that targeting the proton pumping \( bc_1 \) complex leads to a depolarization of \( \Delta \Psi_m \) resulting in a loss of mitochondrial function and parasite death. Thus, in our opinion targeting the mitochondrial ETC leading to a depolarization of \( \Delta \Psi_m \) remains a viable chemotherapeutic strategy. The merit of this strategy is supported by recent evidence showing an up-regulation of parasite expression of mitochondrial ETC components during in vivo growth compared with in vitro culture (Daly et al., 2007; van Doeren and McFadden, 2007).

This study has described a new class of highly selective \( P. falciparum \) inhibitors predicted to target the \( Q_0 \)-site of the \( bc_1 \) complex. The ability of these compounds to additionally disrupt hemozoin formation makes them attractive inhibitors that merit further drug development. This view is strengthened by the potent picomolar antimalarial activity displayed by the recently synthesized haloalkoxyacridones (Winter et al., 2006). Furthermore, we predict that by assessing the inhibitory activity of these molecules against human \( bc_1 \), it may be possible to circumvent toxicological issues previously encountered during the development of other dihydroorucedinediones such as fleroxacin (Raether and Fink, 1982).

Acknowledgments

We thank GlaxoSmithKline for providing the pyrione GW844520 and Dr. Jonathan Vennerstrom (Nebraska Medical Center, Omaha, NE) for supplying the fleroxacin and WR249685. We thank the staff and patients of Ward 7Y and the Gastroenterology Unit, Royal Liverpool Hospital, for their generous donation of blood.

References


Cheng Y and Prusoff WH. (1973) Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099–3108.


Fisher N, Bray PG, Ward SA, and Biagini GA (2008) Malaria-parasite mitochondrial...


Address correspondence to: Giancarlo A. Biagini, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, L3 5QA, UK. E-mail: biagini@liv.ac.uk